



UNIVERSITY OF LEEDS

This is a repository copy of *UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/157392/>

Version: Accepted Version

---

**Article:**

Gilbert, A, Drinkwater, K, McParland, L et al. (7 more authors) (2020) UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes. *European Journal of Cancer*, 128. pp. 7-16. ISSN 0959-8049

<https://doi.org/10.1016/j.ejca.2019.12.022>

---

© 2020, Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

Table 1: Patient characteristics and 1-year outcomes

Patient characteristics	Number of patients (n=187)	%
Median age in years (range)	61 (29-90)	
<b>Gender</b>		
<i>Female</i>	135	72.2
<i>Male</i>	52	27.8
<b>T/N stage*</b>		
<i>T1/2N0</i>	65	34.8
<i>T1/2N+</i>	33	17.6
<i>T3/4N0</i>	29	15.5
<i>T3/4N+</i>	58	31.0
<i>Tx</i>	2	1.1
<b>Smoking status</b>		
<i>Current smoker</i>	41	21.9
<i>Non-smoker</i>	109	58.3
<i>Unknown</i>	37	19.8
<b>HIV status</b>		
<i>HIV negative</i>	73	39.0
<i>HIV positive</i>	7	3.7
<i>Test not performed</i>	107	57.2
<b>Disease status at 1 year (n=109)</b>		
<i>Disease free</i>	84	77.1
<i>Local regional recurrence/failure</i>	13	11.9
<i>Metastatic disease</i>	5	4.6
<i>Dead</i>	6	5.5
<i>Alive unknown disease status</i>	2	1.8
<b>Self-reported stoma status at 1 year (n=113)</b>		
<i>Stoma free</i>	97	85.8
<i>Stoma present</i>	16	14.2
<p>* M1 (n=4): All treated with curative intent IMRT; n=1 low paraaortic lymph node and n=1 perineal satellite nodule (encompassed within RT volume); n=1 solitary lung metastasis removed surgically; n=1 no data available on detail of metastatic disease at presentation or at 1-year follow up (T3N0)</p>		

Table 2: Treatment characteristics and PRO completion

Treatment characteristics	Number of patients (n=187) %	
<b>Radiotherapy technique</b>		
<i>IMRT</i>	81	43.3
<i>Tomotherapy</i>	30	16.0
<i>VMAT / IMAT</i>	76	40.6
<b>Chemotherapy regime</b>		
<i>Mitomycin 5FU</i>	114	61.0
<i>MMC Capecitabine</i>	58	31.0
<i>Other</i>	8	4.3
<i>No chemotherapy</i>	7	3.7
<b>Any G3/4 toxicity</b>		
<i>No G3/4 toxicity</i>	74	39.6
<i>Any G3/4 toxicity</i>	77	41.2
<i>Unknown</i>	36	19.3
<hr/>		
PRO completion	Number of patients (n=187) %	
<b>Baseline PRO completion*</b>		
<i>Yes</i>	115	61.5
<i>No</i>	72	38.5
<b>1-year PRO completion*</b>		
<i>Yes</i>	57	30.5
<i>No</i>	130	69.5
<hr/>		
* At least one item completed on PRO questionnaires		

Table 3: 1-year oncological outcomes

	Alive N=103 (%)	Dead at 1 year N=6 (%)	Total N (%)
<b>Gender</b>			
<i>Female</i>	73 (97.3%)	2 (2.7%)	75 (100%)
<i>Male</i>	30 (88.2%)	4 (11.8%)	34 (100%)
<b>Age at start of RT</b>			
<i>&lt;=62</i>	47 (92.2%)	4 (7.8%)	51 (100%)
<i>&gt;62</i>	56 (96.6%)	2 (3.4%)	58 (100%)
<b>T Stage</b>			
<i>T1/2</i>	60 (98.4%)	1 (1.6%)	61 (100%)
<i>T3/4</i>	41 (89.1%)	5 (10.9%)	46 (100%)
<i>Tx</i>	2 (100%)	0 (0.0%)	2 (100%)
<b>N Stage</b>			
<i>Node negative</i>	55 (96.5%)	2 (3.5%)	57 (100%)
<i>Node positive</i>	48 (92.3%)	4 (7.7%)	52 (100%)
<b>Concurrent chemotherapy</b>			
<i>MMC and 5FU</i>	57 (95.0%)	3 (5.0%)	60 (100%)
<i>MMC and Capecitabine</i>	40 (95.2%)	2 (4.8%)	42 (100%)
<i>None</i>	2 (66.7%)	1 (33.3%)	3 (100%)
<i>Other</i>	4 (100%)	0 (0.0%)	4 (100%)
<b>Radiotherapy technique</b>			
<i>IMRT</i>	45 (95.7%)	2 (4.3%)	47 (100%)
<i>Tomotherapy</i>	11 (100%)	0 (0.0%)	11 (100%)
<i>VMAT / IMAT</i>	47 (92.2%)	4 (7.8%)	51 (100%)
<b>Smoking Status</b>			
<i>Current smoker</i>	14 (77.8%)	4 (22.2%)	18 (100%)
<i>Ex/never smoked</i>	66 (98.5%)	1 (1.5%)	67 (100%)
<i>Unknown</i>	23 (95.8%)	1 (4.2%)	24 (100%)

Table 4: PRO scores at baseline and 1-year follow up, clinical significance in score change, mean and paired differences

	Baseline	1 year follow-up	Significance ¥	Mean differences‡	t-value	Probability (two tailed)	Paired differences <sup>§</sup>	t-value	Probability (two tailed)
<b>EORTC-QLQ C30</b>									
<b>FUNCTION: higher scores = improved function (0-100)</b>									
<b>Global health status§</b>									
Mean (s.d.)	64.0 (25.3)	72.8 (19.5)	I-S	8.9 (1.17, 16.6)	2.27	0.02	-0.37 (-7.03, 6.29)	-0.11	0.91
N	106	55		df 159			45		
<b>Physical functioning§</b>									
Mean (s.d.)	81.1 (22.3)	84.0 (20.7)	I-T	2.9 (-4.11, 9.92)	0.81	0.42	-7.19 (-12.8, -1.54)	-2.56	0.01*
N	110	57		df 165			46		
<b>Role functioning§</b>									
Mean (s.d.)	70.9 (32.1)	81.0 (24.1)	I-M	10.1 (0.58, 19.7)	2.09	0.04	2.12 (-7.69, 11.9)	0.43	0.66
N	111	57		df 166			47		
<b>Emotional functioning§</b>									
Mean (s.d.)	69.5 (25.6)	80.3 (23.1)	I-M	10.8 (2.68, 19.0)	2.62	0.01*	5.06 (-2.83, 12.9)	1.29	0.20
N	106	55		df 159			45		
<b>Cognitive functioning§</b>									
Mean (s.d.)	78.8 (22.6)	84.8 (20.9)	I-S	6.07 (-1.15, 13.3)	1.65	0.10	3.33 (-2.37, 9.04)	1.17	0.24
N	106	55		df 159			45		
<b>Social functioning§</b>									
Mean (s.d.)	72.9 (30.5)	76.6 (27.1)	I-T	3.41 (-5.95, 13.3)	0.75	0.44	-4.07 (-12.0, 3.85)	-1.03	0.30
N	106	55		df 159			45		
<b>SYMPTOMS: higher scores = worse symptoms (0-100)</b>									
<b>Fatigue</b>									
Mean (s.d.)	33.6 (29.3)	26.2 (22.8)	I-S	-7.39 (-16.2, 1.46)	-1.64	0.10	0.23 (-7.19, 7.66)	0.06	0.94
N	110	56		df 164			47		

	Baseline	1 year follow-up	Significance ¥	Mean differences‡	t-value	Probability (two tailed)	Paired differences <sup>§</sup>	t-value	Probability (two tailed)
<b>Nausea and vomiting</b>									
Mean (s.d.)	9.6 (20.0)	4.09 (10.5)	I-S	-5.51 (-11.1, 0.09)	-1.94	0.05	-1.41 (-4.92, 2.09)	-0.81	0.42
N	111	57		df 166			47		
<b>Pain</b>									
Mean (s.d.)	32.0 (32.2)	15.5 (23.7)	I-M	-16.5 (-26.1, -6.9)	-3.39	0.001*	-9.21(-18.5, 0.06)	-1.99	0.05
N	111	56		df 165			47		
<b>Dyspnoea</b>									
Mean (s.d.)	12.3 (23.0)	14.0 (23.3)	D-T	1.68 (-5.91, 9.28)	0.43	0.66	6.38 (-2.18, 14.9)	1.49	0.14
N	108	57		df 163			47		
<b>Insomnia</b>									
Mean (s.d.)	33.9 (31.4)	25.7 (30.8)	I-S	-8.2 (-18.2, 1.85)	-1.61	0.11	-5.67 (-14.8, 3.52)	-1.24	0.22
N	111	57		df 166			47		
<b>Appetite loss</b>									
Mean (s.d.)	21.8 (30.4)	8.9 (19.5)	I-M	-12.9 (-21.7, -4.05)	-2.88	0.005*	-5.79 (-12.8, 1.21)	-1.66	0.10
N	110	56		df 164			46		
<b>Constipation</b>									
Mean (s.d.)	26.7 (34.4)	9.9 (18.8)	I-M	-16.8 (-26.5, -7.1)	-3.41	0.0008*	-14.1 (-23.7, -4.66)	-3.00	0.004*
N	111	57		df 166			47		
<b>Diarrhoea</b>									
Mean (s.d.)	20.1 (31.0)	18.2 (22.9)	I-T	-1.9 (-11.3, 7.4)	-0.41	0.68	3.70 (-7.63, 15.0)	0.65	0.51
N	106	55		df 159			45		
<b>Financial problems</b>									
Mean (s.d.)	22.0 (33.1)	16.3 (23.8)	I-S	-5.64 (-15.5, 4.30)	-1.12	0.26	2.22 (-5.87, 10.3)	0.65	0.51
N	106	55		df 159			45		

	Baseline	1 year follow-up	Significance ¥	Mean differences‡	t-value	Probability (two tailed)	Paired differences <sup>§</sup>	t-value	Probability (two tailed)
<b>EORTC-QLQ C29</b>									
<b>FUNCTION: higher scores = improved function (0-100)</b>									
<b>Body Image§</b>									
Mean (s.d.)	76.7 (28.7)	76.0 (28.9)	<b>D-T</b>	-0.69 (-10.0, 8.62)	-0.14	0.88	-5.81 (-13.4, 1.85)	-1.52	0.13
N	112	56		df 166			43		
<b>Health anxiety§</b>									
Mean (s.d.)	46.8 (33.1)	60.7 (29.2)	<b>I-M</b>	13.9 (3.6, 24.2)	2.68	0.008*	12.5 (0.64, 24.5)	2.12	0.03
N	114	56		df 168			45		
<b>Weight worries§</b>									
Mean (s.d.)	77.4 (30.8)	75.5 (29.4)	<b>D-T</b>	-1.89 (-11.6, 7.91)	-0.38	0.70	-2.27 (-12.3, 7.83)	-0.45	0.65
N	114	56		df 168			44		
<b>Male libido (sexual interest)§</b>									
Mean (s.d.)	32.0 (30.5)	28.8 (27.7)	<b>D-T</b>	-3.16 (-22.5, 16.2)	-0.32	0.74	-3.81e-07 (-29.7, 29.7)	0.00	1.00
N	26	15		df 39			10		
<b>Female libido (sexual interest)§</b>									
Mean (s.d.)	12.2 (23.6)	18.9 (26.6)	<b>I-S</b>	6.63 (-3.15, 16.4)	1.34	0.18	5.437 (-7.28, 18.0)	0.86	0.39
N	76	37		df 111			31		
<b>SYMPTOMS: higher scores = worse symptoms (0-100)</b>									
<b>Urinary frequency</b>									
Mean (s.d.)	38.1 (26.0)	32.7 (22.0)	<b>I-S</b>	-5.4 (-13.4, 2.6)	-1.33	0.19	2.22 (-5.66, 10.1)	0.56	0.57
N	115	56		df 169			45		
<b>Blood/Mucous in stools</b>									
Mean (s.d.)	24.8 (26.1)	14.6 (17.9)	<b>I-M</b>	-10.2 (-17.9, -2.5)	-2.63	0.009*	-8.51 (-15.8, -1.15)	-2.33	0.02
N	115	56		df 169			45		
<b>Bowel Frequency</b>									
Mean (s.d.)	19.9 (19.4)	20.0 (20.9)	<b>D-T</b>	0.08 (-7.3, 7.4)	0.02	0.98	3.33 (-6.36, 13.0)	0.69	0.48
N	82	45		df 125			35		

	Baseline	1 year follow-up	Significance ¥	Mean differences‡	t-value	Probability (two tailed)	Paired differences <sup>§</sup>	t-value	Probability (two tailed)
<b>Urinary incontinence</b>									
Mean (s.d.)	9.1 (20.4)	13.1 (21.7)	<b>D-T</b>	4.03 (-2.7, 10.8)	1.18	0.24	8.33 (1.37, 15.2)	2.41	0.02
N	114	56		df 168			44		
<b>Dysuria</b>									
Mean (s.d.)	9.27 (22.7)	2.97	<b>I-S</b>	-6.29 (-12.5,-0.03)	-1.98	0.04	-3.70 (-9.02, 1.62)	-1.40	0.16
N	115	56		df 169			45		
<b>Abdominal pain</b>									
Mean (s.d.)	12.7 (23.4)	9.52 (18.7)	<b>I-T</b>	-3.20 (-10.3, 3.92)	-0.88	0.37	-1.55 (-7.45, 4.35)	-0.53	0.59
N	110	56		df 164			43		
<b>Buttock pain</b>									
Mean (s.d.)	45.6 (36.0)	23.3 (25.3)	<b>I-L</b>	-22.4 (-33.0, -11.8)	-4.16	0.0001*	-12.5 (-25.4, 0.26)	-1.97	0.05
N	114	56		df 168			45		
<b>Dry mouth</b>									
Mean (s.d.)	28.2 (34.4)	23.2 (32.9)	<b>I-S</b>	-5.05 (-16.0, 5.91)	-0.91	0.36	-3.03 (-15.1, 9.10)	-0.50	0.61
N	112	56		df 166			44		
<b>Hair loss</b>									
Mean (s.d.)	2.97 (13.4)	5.3 (13.8)	<b>D-T</b>	2.38 (-2.08, 6.85)	1.05	0.29	2.17 (-4.41, 4.41)	0.00	1.00
N	101	56		df 155			38		
<b>Taste change</b>									
Mean (s.d.)	12.0 (26.7)	10.1 (24.5)	<b>I-T</b>	-1.91 (-10.3, 6.54)	-0.44	0.65	2.43 (-5.84, 10.7)	0.59	0.55
N	108	56		df 162			41		
<b>Flatulence</b>									
Mean (s.d.)	36.1 (30.7)	40.2 (28.3)	<b>D-T</b>	4.04 (-7.0, 15.1)	0.73	0.47	6.66 (-5.37, 18.7)	1.12	0.26
N	84	44		df 126			35		
<b>Faecal incontinence</b>									
Mean (s.d.)	17.9 (25.7)	19.3 (27.0)	<b>D-T</b>	1.4 (-8.3, 11.0)	0.28	0.78	5.71 (-6.85, 18.2)	0.92	0.36
N	82	45		df 125			35		



	Baseline	1 year follow-up	Significance ¥	Mean differences‡	t-value	Probability (two tailed)	Paired differences <sup>§</sup>	t-value	Probability (two tailed)
<b>Anal sore skin</b>									
Mean (s.d.)	29.7 (31.1)	22.7 (30.3)	I-S	-6.90 (-18.3, 4.54)	-1.19	0.23	-0.98 (-13.7, 15.7)	0.13	0.89
N	81	55		df 123			34		
<b>Bowel embarrassment</b>									
Mean (s.d.)	19.6 (27.9)	25.2 (31.9)	D-S	5.6 (-5.2, 16.4)	1.02	0.31	9.52 (-2.76, 21.8)	1.57	0.12
N	80	45		df 123			35		
<b>Impotence</b>									
Mean (s.d.)	37.2 (43.5)	46.7 (39.4)	D-S	9.5 (-18.1, 37.1)	0.69	0.49	-6.66 (-46.8, 33.5)	-0.37	0.71
N	26	15		df 39			10		
<b>Dyspareunia</b>									
Mean (s.d.)	14.5 (27.8)	29.5 (38.0)	D-M	15.0 (-0.6, 30.6)	1.92	0.06	17.9 (0.28, 35.6)	2.21	0.04
N	46	26		df 70			13		
§ Function scores: higher scores = improved function; * P-values with <0.01 significance; †Unpaired t-test; §Paired t-test; ¥ Significance - D deterioration; I improvement; S small (5-10); M moderate (10-20); L large (>20); T Trivial (<5)									